Decline in HIV infectivity following the introduction of highly active antiretroviral therapy
- PMID: 15090833
- PMCID: PMC2442908
- DOI: 10.1097/00002030-200401020-00010
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy
Abstract
Objective: Little is known about the degree to which widespread use of antiretroviral therapy in a community reduces uninfected individuals' risk of acquiring HIV. We estimated the degree to which the probability of HIV infection from an infected partner (the infectivity) declined following the introduction of highly active antiretroviral therapy (HAART) in San Francisco.
Design: Homosexual men from the San Francisco Young Men's Health Study, who were initially uninfected with HIV, were asked about sexual practices, and tested for HIV antibodies at each of four follow-up visits during a 6-year period spanning the advent of widespread use of HAART (1994-1999).
Methods: We estimated the infectivity of HIV (per-partnership probability of transmission from an infected partner) using a probabilistic risk model based on observed incident infections and self-reported sexual risk behavior, and tested the hypothesis that infectivity was the same before and after HAART was introduced.
Results: A total of 534 homosexual men were evaluated. Decreasing trends in HIV seroincidence were observed despite increases in reported number of unprotected receptive anal intercourse partners. Conservatively assuming a constant prevalence of HIV infection between 1994 and 1999, HIV infectivity decreased from 0.120 prior to widespread use of HAART, to 0.048 after the widespread use of HAART- a decline of 60% (P=0.028).
Conclusions: Use of HAART by infected persons in a community appears to reduce their infectiousness and therefore may provide an important HIV prevention tool.
Conflict of interest statement
Note: Conflict of interest statement: the authors declare that there are no financial conflicts of interest.
References
-
- Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081–1090. - PubMed
-
- Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725–733. - PubMed
-
- Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921–929. - PubMed
-
- Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–1180. - PubMed
-
- Brocklehurst P, Volmink J. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2002;2:CD003510. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 MH062246/MH/NIMH NIH HHS/United States
- M01 RR000079/RR/NCRR NIH HHS/United States
- P30 AI277763/AI/NIAID NIH HHS/United States
- 5R01-DA13510/DA/NIDA NIH HHS/United States
- R01 DE012911/DE/NIDCR NIH HHS/United States
- R01 DA013510/DA/NIDA NIH HHS/United States
- 5R01-DE12911-03/DE/NIDCR NIH HHS/United States
- M01 RR00083/RR/NCRR NIH HHS/United States
- P30 AI027763/AI/NIAID NIH HHS/United States
- M02 RR00079/RR/NCRR NIH HHS/United States
- M01 RR000083/RR/NCRR NIH HHS/United States
- P30 MH62246/MH/NIMH NIH HHS/United States
- P30 AI27763/AI/NIAID NIH HHS/United States
- U01-CA78124/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical